TNFSF13B and myeloid sarcoma: A statistically significant association between the level of serum BAFF protein in MS patients negative to MAP_402718–32 and BAFF levels in MS patients with MP therapy, negative and positive to MAP_402718–32 was also observed (Dunn’s multiple comparison test p = 0.011 and p = 0.019 respectively; Fig. 3E).